Potassium Chloride Extended Release Tablets

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-26-D-0001

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

NONE

Place of Performance

Maple Grove, Minnesota, UNITED STATES

SourceSAM
Documents1
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued an award notice for the procurement of Potassium Chloride Extended Release (ER) Tablets. This contract, identified by procurement number SPE2D2-26-D-0001, pertains to the supply of pharmaceutical preparations, specifically Potassium Chloride ER Tablets, which are essential for various medical and therapeutic applications within the federal supply chain. The scope of this procurement encompasses the manufacturing and delivery of Potassium Chloride ER Tablets, aligning with NAICS code 325412 (Pharmaceutical Preparation Manufacturing, 2022 version) and Product Service Code 6505, which covers drugs and biologicals. The place of performance for this contract is Maple Grove, Minnesota, indicating that manufacturing, distribution, or fulfillment activities will be centered in this location. The primary objective of this procurement is to ensure a reliable and consistent supply of Potassium Chloride ER Tablets to meet the operational and medical needs of the Department of Defense and associated federal entities. Contractors are expected to adhere to stringent quality standards typical of pharmaceutical manufacturing, ensuring that all deliverables comply with applicable federal regulations and industry best practices. This opportunity is not subject to any set-aside restrictions, making it open to all qualified vendors without preference for small businesses or other socioeconomic categories. The procurement is managed by DLA Troop Support, a federal office specializing in the acquisition and distribution of critical supplies for defense operations. Key contacts for this contract include Ryan Guarnere ([email protected], 445-737-1729) and Jason Wray ([email protected], 445-737-6304), who can provide further information regarding contract administration and technical requirements. Contractors considering this opportunity should have robust capabilities in pharmaceutical preparation manufacturing, with the ability to meet federal quality and delivery standards. The contract is currently active, and further details, including attachments, can be accessed via the official SAM.gov listing (Opportunity ID: b84638d7dddc4ba29209baafaa369016). This award represents a critical component of the federal government’s commitment to maintaining a secure and effective supply of essential pharmaceuticals for defense and related agencies.